Jiuzhou Pharma/九洲药业

Zhejiang Jiuzhou Pharmaceutical Co., LTD. (stock code: 603456.SH), founded in 1998 and headquartered in Taizhou, Zhejiang, is a leading CDMO and generic drug manufacturer in China. The company has production bases in Taizhou and Hangzhou in Zhejiang Province, Yancheng and Suzhou in Jiangsu Province, Zhongshan in Guangdong Province, and R & D centers in Hangzhou，Taizhou，Nanjing and North Carolina, USA，Kanagawa, Japan，Konstanz, Germany.It has built industry-leading R&D and innovation platforms such as national Enterprise Technology Center, National Post-doctoral Research Workstation, National CNAS Laboratory, Zhejiang Provincial Key Enterprise Research Institute, Zhejiang Provincial Academician Expert Workstation and Zhejiang Provincial First Batch of Foreign expert workstation. It has been awarded Top 100 Chinese Pharmaceutical Industry Enterprises, Top 20 Chinese CXO Companies, National LEADING API Export Enterprise, National Technology Innovation Demonstration Enterprise, national green factory, and high quality supplier and partner in the international market. Jiuzhou Pharmaceutical Co., LTD. is a leader in the global specialty API industry. The company's key products carbamazepine, Ketoprofen, Gliclazide, sulfanilamide series products and other characteristic API products are ranked in the forefront of the global market share of single variety segment. After years of development and cultivation, the company’s CDMO business is booming, innovative drug customization partners throughout the world. Based on the international leading key technologies of green pharmaceutical and the cGMP quality control system in line with international standards, as well as the standard and perfect environmental protection, health and safety management system (EHS), Jiuzhou Pharmaceutical is striving to build a global CDMO brand and build an “integrated service ecosystem” of CDMO API and preparation.Jiuzhou pharmaceutical always adheres to the strategy of innovation-driven development